Promomed increased its net profit under IFRS for the first half of 2025 by 283 times to 1.418 billion rubles from 5 million rubles a year earlier. This is stated in the company's message.
Revenue increased by 82% to 12.97 billion rubles from 7.13 billion rubles, gross profit – by 91.6% to 7.968 billion rubles from 4.16 billion rubles, EBITDA – by 91% to 4.368 billion rubles from 2.285 billion rubles.
The total number of employees of the group as of June 30, 2025 increased by 16% to 2,491 thousand people compared to 2,151 thousand people as of June 30, 2024.
Promomed is a biopharmaceutical company. The main activities of the group are the production, development and wholesale of pharmaceutical products. The Group's production facilities are located in the cities of Saransk and Obninsk, Russian Federation.
Promomed Group was initially established by several individuals as a group of companies operating in the pharmaceutical market of the Russian Federation.
PJSC Promomed (the parent company of the group) was established on July 16, 2021.
As of December 31, 2024 and December 31, 2023, the ultimate controlling owner of the group was Peter Bely. As of December 31, 2024, he owns 87.67% of the authorized capital. The share of 5.65% belongs to Promomed Holdings LLC, 6.68% is under nominal holding.
According to RAS, in 2024, the loss of PJSC Promomed amounted to 38.552 million rubles against a loss of 116.492 million rubles.
Promomed's profit for 2024 under IFRS decreased by 3% to 2.87 billion rubles from 2.97 billion rubles a year earlier. Revenue increased by 35% to RUB 21.449 billion from RUB 15.842 billion.
